List of Contents

Wound Care Biologics Market Size, Share, and Trends 2024 to 2033

Wound Care Biologics Market (By Wound Type: Chronic Wound, Acute Wound; By Product: Topical Agents, Biological Skin Substitutes; By End User: Hospitals and Clinics, Wound Centers and Burn Centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : March 2024
  • Report Code : 3921
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Wound Care Biologics Market 

5.1. COVID-19 Landscape: Wound Care Biologics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Wound Care Biologics Market, By Wound Type

8.1. Wound Care Biologics Market, by Wound Type, 2024-2033

8.1.1 Chronic Wound

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Acute Wound

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Wound Care Biologics Market, By Product

9.1. Wound Care Biologics Market, by Product, 2024-2033

9.1.1. Topical Agents

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Biological Skin Substitutes

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Wound Care Biologics Market, By End User 

10.1. Wound Care Biologics Market, by End User, 2024-2033

10.1.1. Hospitals and Clinics

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Wound Centers and Burn Centers

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Wound Care Biologics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.1.2. Market Revenue and Forecast, by Product (2021-2033)

11.1.3. Market Revenue and Forecast, by End User (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.2.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End User (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.3.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End User (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End User (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Wound Type (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End User (2021-2033)

Chapter 12. Company Profiles

12.1. Stryker Corporation

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. MIMEDX Group, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Lavior Pharma Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Skye Biologics Holdings, LLC

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Integra LifeSciences Holdings Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. ORGANOGENESIS HOLDINGS INC.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. ConvaTec Group plc

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Tissue Regenix Group Plc

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Kerecis

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Smith & Nephew plc

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client